Yongqing Y Liu

US Patent:

20130312130, Nov 21, 2013

Filed:

Sep 23, 2011

Appl. No.:

13/976879

Inventors:

Douglas Dean - Prospect KY, US
Yongqing Liu - Louisville KY, US

Assignee:

UNIVERSITY OF LOUISVILLE - Louisville

International Classification:

C12N 5/074
A61D 19/04

US Classification:

800 18, 435377, 435357, 435366, 800 14, 424 937, 600 34

Abstract:

Provided are methods for producing a reprogrammed fibroblast or epithelial cell. The methods include growing a plurality of fibroblasts or epithelial cells in monolayer culture to confluency; and disrupting the monolayer culture to place at least a fraction of the plurality of fibroblasts or epithelial cells into suspension culture under conditions sufficient to form one or more embryoid body-like spheres, wherein the one or more embryoid body-like spheres comprise one or more reprogrammed fibroblasts or epithelial cells that express one or more markers not expressed prior to the disrupting step. Also provided are reprogrammed fibroblasts or epithelial cells produced by the disclosed methods, formulations that include reprogrammed fibroblasts or epithelial cells, methods for using the reprogrammed fibroblasts or epithelial cells, methods for producing chimeric non-human mammals that include one or more sphere-induced Pluripotent Cells (siPS), and chimeric non-human mammals produced thereby.

US Patent:

20110243898, Oct 6, 2011

Filed:

Nov 22, 2010

Appl. No.:

12/951678

Inventors:

Douglas Dean - Prospect KY, US
Yongqing Liu - Louisville KY, US

Assignee:

The University of Louisville Research Foundation, Inc. - Louisville KY

International Classification:

A61K 35/12
C12N 5/0775

US Classification:

424 937, 435357, 435366, 435377

Abstract:

Provided are methods for producing a reprogrammed fibroblast. The methods can include growing a plurality of fibroblasts in monolayer culture to confluency; and disrupting the monolayer culture to place at least a fraction of the plurality of fibroblasts into suspension culture under conditions sufficient to form one or more embryoid body-like spheres, wherein the one or more embryoid body-like spheres comprise one or more reprogrammed fibroblasts that express one or more markers not expressed by a fibroblast growing in the monolayer culture prior to the disrupting step. Also provided are reprogrammed fibroblasts produced by the disclosed methods, formulations that include reprogrammed fibroblasts, and methods for treating an injury to a tissue in a subject by administering to a subject in need thereof a composition of reprogrammed fibroblast cells in a pharmaceutically acceptable carrier.